ReviewJournal of nephrology2021
SGLT2 inhibitors, sodium and off-target effects: an overview.
Review in Journal of nephrology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- Pharmacokinetics of Henagliflozin in Dialysis Patients with Diabetes.Clinical pharmacokinetics · 2023Trial
- The Potential Role of SGLT2 Inhibitors in the Treatment of Depression: Mechanisms and Clinical Prospects.Drug design, development and therapy · 2026Review
- Reduced Incidence of Aortic Dissection in Patients With Type 2 Diabetes Treated With Sodium Glucose Transporter 2 Inhibitors.Journal of the American Heart Association · 2025Article
- Magnitude and determinants of isolated systolic hypertension among type 2 diabetes patients in selected referral hospitals in Amhara Region, Ethiopia.Scientific reports · 2025Article
- The protective role of SGLT2 inhibitors on aortic aneurysm mediated by oxidative stress and inflammation in type 2 diabetes mellitus.Cardiovascular diabetology · 2025Article
- Sodium-Glucose Cotransporter 2 Inhibitors for Mesenchymal-Epithelial Transition Inhibitor-Induced Edema.Thoracic cancer · 2025Article
- Rediscovery of the implication of albuminuria in heart failure: emerging classic index for cardiorenal interaction.ESC heart failure · 2024Review
- Article
- Article
- The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials.Pharmaceutics · 2023Review
- Anti-Inflammatory Properties of the SGLT2 Inhibitor Empagliflozin in Activated Primary Microglia.Cells · 2022Article
- Review of SGLT2i for the Treatment of Renal Complications: Experience in Patients with and Without T2D.Diabetes therapy : research, treatment and education of diabetes and related disorders · 2022Review
- Canagliflozin promotes osteoblastic MC3T3-E1 differentiationFrontiers in endocrinology · 2022Article
- Recent Advances in Diabetic Kidney Diseases: From Kidney Injury to Kidney Fibrosis.International journal of molecular sciences · 2021Review
- NQO1 Deficiency Aggravates Renal Injury by Dysregulating Vps34/ATG14L Complex during Autophagy Initiation in Diabetic Nephropathy.Antioxidants (Basel, Switzerland) · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are a relatively new class of antidiabetic drugs that in addition to emerging as an effective antihyperglycemic treatment have been shown to improve, in several trials, both renal and cardiovascular outcomes. In consideration of the renal site of action and the associated osmotic diuresis, a negative sodium balance has been postulated during SGLT2i administration. Actually, sodium and water depletion may contribute to some positive actions of SGLT2i but evidence is far from being conclusive and the real physiologic effects of SGLT2i on sodium remain largely unknown. Indeed, no study has yet investigated how SGLT2i change sodium balance in the long term and especially the pathways through which the natriuretic effect is expressed. Furthermore, several experimental studies have recently identified different pathways, not directly linked to tubular sodium handling, which could contribute to the renal and cardiovascular benefits associated with SGLT2i. This paper will review the evidence of SGLT2i action on sodium transporters, their off-target effects and their potential role on kidney protection.
Indexed as
Identifiers
32870494What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.